Radium-223 (Xofigo ®) with Concurrent Abiraterone or Enzalutamide: Predictive Biomarkers of Improved Overall Survival in a Clinically Advanced Cohort

Prostate cancer remains the second leading cause of cancer death in men with 26,120 deaths annually, accounting for approximately 8% of all male cancer related deaths1. With modern therapies and improved early detection, the 5-year relative survival rate for localized disease has approached 100%, but declines to only 28% for patients diagnosed at distant stages2. Despite promising new therapeutic regimens3 –5, most patients eventually progress to an androgen-insensitive state4,7. Patients with metastatic castrate-resistant prostate cancer (mCRPC) commonly have radiographic evidence of osteoblastic8 bone metastases9–11.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research